オプションチェーンは、Apollomicsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Apollomicsの市場センチメントを評価します。.

Apollomics (NASDAQ:APLM) 株価情報, オプションチェーン

Apollomics

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics Inc. - Class A Ordinary Shares

Apollomics Inc

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Market Outperform and maintains $28 price target.

News

Price Target

Reiteration

Analyst Ratings

KURA

JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target

American International Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) has outperformed the market over the past 5 years by 1.63% on an annualized basis producing an average annual return of 15.93%. Currently, American International Gr has a market capitalization of $48.61 billion. 
Buying $1000 In AIG: If an investor had bought $1000 of AIG stock 5 years ago, it would be worth $2,083.69 today based on a price of $81.93 for AIG at the time of writing.
<h3>American International Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745944218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning American International Gr Stock In The Last 5 Years

<a href="https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs">https://www.aboutamazon.com/news/retail/amazon-response-to-white-house-tariffs</a>

General

AMZN

"The team that runs our ultra low cost Amazon Haul store considered the idea of listing import charges on certain products. This was never approved and is not going to happen."- Amazon

JMP Securities analyst Steven DeLaney reiterates Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) with a Market Outperform and maintains $15 price target.

FBRT

JMP Securities Reiterates Market Outperform on Franklin BSP Realty Trust, Maintains $15 Price Target

Truist Securities analyst Michael Ciarmoli maintains Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) with a Buy and raises the price target from $205 to $209.

Truist Securities Maintains Buy on Woodward, Raises Price Target to $209

Truist Securities analyst Gregory Miller maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and lowers the price target from $22 to $19.

Truist Securities Maintains Buy on OneSpaWorld Hldgs, Lowers Price Target to $19

Truist Securities analyst Srikripa Devarakonda maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $210 to $199.

BIIB

Truist Securities Maintains Buy on Biogen, Lowers Price Target to $199

Zebra Technologies Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock gained on Tuesday after it reported financial results for&nbsp;<a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the </a>first <a href="https://www.benzinga.com/pressreleases/25/04/b45061743/zebra-technologies-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">quarter</a>. Here's what you need to know.
The mobile computing company reported quarterly sales of $1.31 billion, up by 11.3%, beating analyst estimates of $1.29 billion.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" target="_blank" rel="noreferrer noopener">Zebra Tech Q4 Earnings: Revenue Surges 32%, CEO Cites Strong Retail Demand</a>
Zebra reported adjusted earnings of $4.02 per share, exceeding&nbsp;analyst estimates of $3.62.
Zebra's two main business segments also saw substantial growth during the period. The Enterprise Visibility &amp; Mobility segment recorded net sales of $846 million, up 8% from the previous year. The Asset Intelligence &amp; Tracking segment recorded net sales of $462 million, up 17.9% from the previous year.
The consolidated adjusted gross margin increased 150 bps to 49.6%, primarily due to volume leverage and business mix. Adjusted EBITDA margin expanded by 240 bps to 22.3%.
The company said it had $879 million in cash and cash equivalents as of March 29.
CEO Bill Burns said demand trends continued to be positive into the second quarter, and the company left its full-year outlook unchanged, except for the direct cost of tariffs.&nbsp;
Outlook:&nbsp;For the second quarter, Zebra expects sales growth of 4%-7% or $1.25 billion-$1.30 billion versus the&nbsp;$1.28 billion estimate. The company expects adjusted earnings of $3-$3.50 per share <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus estimates of</a> $3.52.
The company reiterated fiscal 2025 net sales growth of 3%-7% or $5.13 billion-$5.33 billion versus the $5.37 billion estimate. It expects adjusted earnings of $13.75-$14.75 (<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43705227/zebra-tech-q4-earnings-revenue-surges-32-ceo-cites-strong-retail-demand" rel="noreferrer noopener">prior $14.75-$15.25</a>) per share versus the $15.89 per share estimate.
ZBRA Price Action:&nbsp;Zebra stock is up 6.57% at 259.49 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" target="_blank" rel="noreferrer noopener">Alibaba Bets Big On AI With New Cloud Tools As Jack Ma Reemerges In Company Comeback</a></li>
</ul>
Photo: JHVEPhoto via Shutterstock

Earnings

Guidance

Movers

ZBRA

Zebra Stock Rises As Strong Retail Demand, Sales Beat Drive Big Quarter, But Tariffs Cloud Full-Year Outlook

JMP Securities analyst Silvan Tuerkcan reiterates enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Market Outperform and maintains $18 price target.

ENGN

JMP Securities Reiterates Market Outperform on enGene Holdings, Maintains $18 Price Target

B of A Securities analyst Allen Lutz maintains Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Underperform and raises the price target from $22 to $26.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $26

B of A Securities analyst Jean Ann maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underperform and raises the price target from $49 to $50.

B of A Securities Maintains Underperform on Cheniere Energy Partners, Raises Price Target to $50

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $46 price target.

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $46 Price Target

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

JMP Securities Reiterates Market Outperform on Broadstone Net Lease, Maintains $21 Price Target

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.58% on an annualized basis producing an average annual return of 11.78%. Currently, AbbVie has a market capitalization of $344.00 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $300.66 today based on a price of $194.46 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745943312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Citigroup analyst Paul Diamond initiates coverage on Diversified Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) with a Buy rating and announces Price Target of $16.

Initiation

Citigroup Initiates Coverage On Diversified Energy with Buy Rating, Announces Price Target of $16

B of A Securities analyst Jean Ann Salisbury maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Buy and raises the price target from $254 to $258.

B of A Securities Maintains Buy on Cheniere Energy, Raises Price Target to $258

B of A Securities analyst Jean Ann Salisbury maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $14 to $12.

B of A Securities Maintains Buy on Venture Global, Lowers Price Target to $12

Citigroup analyst Patrick Cunningham maintains LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) with a Neutral and lowers the price target from $66 to $58.

Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $58

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) announced a <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-term collaboration</a> on Tuesday.
In March, Novo Nordisk introduced&nbsp;NovoCare Pharmacy, a direct-to-patient delivery service to improve access to Wegovy (semaglutide) for&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44143391/novo-nordisk-boosts-wegovy-access-with-lower-pricing-and-home-delivery" rel="noreferrer noopener">cash-paying patients</a>.
Americans can now access NovoCare Pharmacy directly through the Hims &amp; Hers platform. A bundled offering of all dose strengths of Wegovy and a Hims &amp; Hers membership, which includes access to 24/7 care, ongoing clinical support, and <a href="https://www.benzinga.com/pressreleases/25/04/b45063485/hims-hers-and-novo-nordisk-team-up-to-expand-affordable-access-to-care" target="_blank" rel="noreferrer noopener">nutrition guidance</a>.
In March, Novo Nordisk announced updates to the Wegovy&nbsp;savings program, allowing all eligible cash-paying patients to access Wegovy&nbsp;(semaglutide) injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44455562/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wego" rel="noreferrer noopener">cost of&nbsp;$499&nbsp;per month</a>.
Previously, the&nbsp;$499-per-month offer for Wegovy&nbsp;was only available via the recently launched NovoCare&nbsp;Pharmacy.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45019869/novo-nordisk-wins-legal-battle-to-curb-unsafe-knockoff-versions-of-ozempic-wegovy" rel="noreferrer noopener">Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy</a>
On Tuesday, the company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims &amp; Hers platform.
The companies are also developing a roadmap that combines Novo Nordisk&#8217;s treatments with Hims &amp; Hers&#8217; ability to scale access to quality care, aiming to improve long-term outcomes for more people.
This new offering builds on Hims &amp; Hers&#8217; existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
The platform will continue to offer access to other medications, oral kits, protein, nutrition kits, and clinically-backed care plans.
Earlier in April, Hims &amp; Hers Health said it would offer Eli Lilly And Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound <a href="https://www.benzinga.com/25/04/44593851/hims-hers-health-stock-jumped-tuesday-afternoon-what-happened" target="_blank" rel="noreferrer noopener">through its Telehealth platform</a>.
In a blog post, Hims &amp; Hers announced that it's expanding access to personalized weight loss care.
Hims &amp; Hers said its GLP-1 offering generated over $225 million in <a href="https://www.benzinga.com/general/health-care/25/03/44144092/why-is-hims-hers-health-stock-trading-lower-on-wednesday" target="_blank" rel="noreferrer noopener">revenue in 2024</a>.
Price Action: HIMS stock is up 35.5% at $38.60 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45065830/ups-delivers-mixed-bag-q1-supply-chain-weakness-offset-by-strong-domestic-and-international-growth" target="_blank" rel="noreferrer noopener">UPS Delivers Mixed Bag: Q1 Supply Chain Weakness Offset By Strong Domestic And International Growth</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

Contracts

Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform

B of A Securities analyst Vivek Arya maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Buy and raises the price target from $320 to $350.

CDNS

B of A Securities Maintains Buy on Cadence Design Systems, Raises Price Target to $350

Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data

Press Releases

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split

Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Comments

Apollomics

Apollomics (APLM) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル